Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct(®))

BACKGROUND: Extended half-life (EHL) factor VIII (FVIII)-replacement therapies enable patients with haemophilia A to maintain higher activity levels with fewer injections. N8-GP (turoctocog alfa pegol; Esperoct(®)) is an EHL product derived from conjugation of polyethylene glycol (PEG) to a recombin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjørnsdottir, Inga, Støvring, Birgitte, Søeborg, Tue, Jacobsen, Helene, Sternebring, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221073/
https://www.ncbi.nlm.nih.gov/pubmed/32152818
http://dx.doi.org/10.1007/s40268-020-00297-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221073/
https://www.ncbi.nlm.nih.gov/pubmed/32152818
http://dx.doi.org/10.1007/s40268-020-00297-1

Ejemplares similares